CRL: Charles River Laboratories International, Inc. Twitter on Stock

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 1, 4:56 PM Charles River (CRL): Q1 EPS of $0.69 misses by $0.02. Revenue of $291.2M misses by $0.34M. (PR) Comment! [Earnings, Breaking News]
Wednesday, February 13, 4:42 PM Charles River (CRL): Q4 EPS of $0.64 beats by $0.04. Revenue of $280.1M misses by $0.71M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, December 13, 2012, 1:25 PM Charles River Labs (CRL +3.2%) moves higher on a couple of upgrades earlier today. JPMorgan raises its rating on the shares to Overweight, saying the risk-reward is looking good going into 2013. The firm notes that longer term questions still remain, but given the improving fundamentals, ongoing cost discipline and a 10% free cash flow yield, the stock looks attractive at current levels. Separately, Wells Fargo also upped the shares to Outperform on valuation, saying that that guidance looks conservative with the midpoint only 5% below consensus. Comment! [Healthcare, On the Move]
Wednesday, December 12, 2012, 12:45 PM Midday top 10 gainers: YMI +77%. DSTI +73%. TELK +25%. LDK +21%. JKS +23%. JASO +21%. TSL +20%. YGE +19%. CBMX +14%. SOL +17%.
Midday top 10 Losers: RSOL -14%. CENT -13%. ACUR -11%. TAS -11%. CATO -10%. CRWS -9%. AVD -9%. CRL -8%. AXK -8%. LTBR -8%. Comment! [On the Move]
Wednesday, December 12, 2012, 9:29 AM Charles River Labs (CRL) -5.1% premarket after providing 2013 earnings guidance below expectations, at $2.80-$2.90 per share vs. $3.01 consensus estimate. The drug research services provider also expects 2012 EPS to come in between the low end and the midpoint of its previously estimated range of $2.68-$2.73. Comment! [Healthcare, On the Move]
Tuesday, October 30, 2012, 4:44 PM Charles River Laboratories International (CRL): Q3 EPS of $0.65 beats by $0.03. Revenue of $278.7M (flat% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
Wednesday, October 17, 2012, 8:28 AM AstraZenica (AZN) chooses Charles River (CRL) as its partner for in vivo biology, which will allow AZN to create a "flexible research platform." The deal is for three years and is expected to contribute approximately 1% to Charles Rivers' total net sales in 2013. (PR) Comment! [Healthcare]
Saturday, October 13, 2012, 10:00 AM Five years after record fundraising for P-E firms, the shops still sit on much of that cash and are coming up against the time when they must "use-it-or-lose-it." As most would rather use it, Barron's screens for attractive targets - market cap of $1B-$10B, an Enterprise Value/EBITDA ratio below 10, and annual cash flow of at least 5% of stock market value. The winners: Guess (GES), Terex (TEX), Charles River Labs (CRL), and Big Lots (BIG). 1 Comment [Quick Ideas, M&A]
Wednesday, August 29, 2012, 2:25 PM Charles River Laboratories (CRL +0.4%) acquires Accugenix , a global provider of cGMP-compliant contract microbial identification testing, for around $17M in cash. The acquisition is intended to strengthen CRL's Endotoxin and Microbial Detection1 portfolio by providing clients with state-of-the-art microbial detection services for manufacturing in the biopharmaceutical, medical device, nutraceutical and consumer care industries. Comment! [Healthcare, M&A]
Tuesday, August 7, 2012, 4:46 PM Charles River Laboratories (CRL): Q2 EPS of $0.75 beats by $0.09. Revenue of $284.7M (-1.2% Y/Y) misses by $2M. (PR) Comment! [Earnings, Healthcare]
Wednesday, May 2, 2012, 5:06 PM Charles River Laboratories (CRL): Q1 EPS of $0.70 beats by $0.05. Revenue of $286M (flat Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
Monday, February 13, 2012, 7:04 PM More on Charles River Labratories (CRL): Q4 beats both revenue and per share estimates on better than expected product demand and the absence of prior-year write-downs. The company also reafirms FY12 guidance. Comment! [Healthcare, Earnings]
Monday, February 13, 2012, 4:52 PM Charles River Laboratories (CRL): Q4 EPS of $0.69 beats by $0.14. Revenue of $291M (+3.3% Y/Y) beats by $9M. Shares +2.6% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
Wednesday, January 11, 2012, 4:30 PM With speculation high that Charles River Labs (CRL) is in play, William Blair estimates a deal could be worth at least $40 and maybe more than $60, with the most likely price in the mid-$40s (today's close was $31.34). Shares fell 3.5% today, but remain up 13% on the week. Comment! [M&A, Healthcare]
Tuesday, January 10, 2012, 11:25 AM Speculation that Charles River Laboratories (CRL) is in play intensifies as management stays mum, shares are now up 22.8% without breaking stride. Comment! [On the Move]
Tuesday, January 10, 2012, 8:23 AM Charles River Labs (CRL) is pursuing a sale of the company that could fetch as much as $40/share, and it's "just a matter of time" before a deal is completed, the Deal Reporter says. R.W. Baird expects shares to trade higher on the speculation unless management denies the story. CRL +2.1% premarket. Comment! [Healthcare, M&A, On the Move]

CRL Charles River Laboratories International, Inc.

CRL

Charles River Laboratories International, Inc.